1. Home
  2. DCOY vs EOCN Comparison

DCOY vs EOCN Comparison

Compare DCOY & EOCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Decoy Therapeutics Inc. Common Stock

DCOY

Decoy Therapeutics Inc. Common Stock

N/A

Current Price

$1.56

Market Cap

3.2M

Sector

Health Care

ML Signal

N/A

EOCN

Eocene Ltd. Ordinary Shares

N/A

Current Price

$3.38

Market Cap

3.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DCOY
EOCN
Founded
N/A
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2M
3.6M
IPO Year
2014
2013

Fundamental Metrics

Financial Performance
Metric
DCOY
EOCN
Price
$1.56
$3.38
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 4.1M
5.0K
Earning Date
11-16-2026
11-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$20.42
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$3.12
52 Week High
$13.51
$3.80

Technical Indicators

Market Signals
Indicator
DCOY
EOCN
Relative Strength Index (RSI) 29.82 46.92
Support Level $0.61 $3.12
Resistance Level $3.29 $3.80
Average True Range (ATR) 0.69 0.24
MACD -0.10 -0.01
Stochastic Oscillator 0.33 51.96

Price Performance

Historical Comparison
DCOY
EOCN

About DCOY Decoy Therapeutics Inc. Common Stock

Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.

About EOCN Eocene Ltd. Ordinary Shares

Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.

Share on Social Networks: